UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): ~~June~~July 128, 2020

Novelion Therapeutics Inc.

(Exact Name of Registrant as specified in its charter)

British Columbia, Canada		000-17082		98-0455702
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

c/o ~~Norton~~Alvarez ~~Rose~~& ~~Fulbright~~Marsal Canada Inc.

~~1800~~Commerce -Place ~~510~~400 ~~West~~Burrard ~~Georgia~~ Street, Suite 1680, Vancouver, BC ~~V6B~~V6C ~~0M3~~3A6 Canada

(Address of principal executive offices)

Registrant’s telephone number, including area code: ~~(877) 764~~604-~~3131~~638-7440

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares, without par value	NVLNF	OTC Markets

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01. Other Events.

On ~~June~~July 128, 2020, ~~Novelion~~ Novelion Therapeutics Inc. issued a press release ~~with~~announcing anthat ~~update~~it ~~regarding~~has ~~its~~ceased ~~voluntary~~to ~~liquidation~~be ~~and~~a ~~dissolution~~reporting issuer under Canadian securities legislation, which press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 8.01 by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated ~~June~~July 128, 2020.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Novelion Therapeutics Inc.


	By:	/s/ Alvarez & Marsal Canada Inc.
	Name:	Alvarez & Marsal Canada Inc.
	Title:	Liquidator, acting solely in such capacity and not in its personal capacity

Date: ~~June~~July 1213, 2020

Filing Compare · NOVELION THERAPEUTICS INC.